It is intriguing that the MSeA and carboplatin co-treatment differentially activates ATM and DNA-PKcs kinases, but inhibition of their kinase activities does not impact on the synergism of MSeA and carboplatin in killing the ovarian cancer cells. Here, ATM is linked to ovarian cancer.